Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

doi:10.3978/j.issn.2223-4683.2015.04.11

Review

. 2015 Jun;4(3):355-64.

doi: 10.3978/j.issn.2223-4683.2015.04.11.

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

Federica Recine¹, Cora N Sternberg¹

Affiliations

PMID: 26816835
PMCID: PMC4708230
DOI: 10.3978/j.issn.2223-4683.2015.04.11

Review

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

Federica Recine et al. Transl Androl Urol. 2015 Jun.

. 2015 Jun;4(3):355-64.

doi: 10.3978/j.issn.2223-4683.2015.04.11.

Authors

Federica Recine¹, Cora N Sternberg¹

Affiliation

¹ Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.

PMID: 26816835
PMCID: PMC4708230
DOI: 10.3978/j.issn.2223-4683.2015.04.11

Abstract

The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer biology. New therapeutic agents and approaches have been evaluated demonstrating benefits in survival and quality of life in patients with metastatic prostate cancer.

Keywords: Prostate cancer; chemotherapy; hormonal therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cited by

Association between insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis.
Qin Z, Li X, Tang J, Jiang X, Yu Y, Wang C, Xu W, Hua Y, Yu B, Zhang W. Qin Z, et al. Onco Targets Ther. 2016 Sep 6;9:5451-9. doi: 10.2147/OTT.S107595. eCollection 2016. Onco Targets Ther. 2016. PMID: 27660462 Free PMC article. Review.
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.
Baser O, Samayoa G, Dwivedi A, AlSaleh S, Cigdem B, Kizilkaya E. Baser O, et al. Acta Oncol. 2024 Apr 9;63:137-146. doi: 10.2340/1651-226X.2024.20337. Acta Oncol. 2024. PMID: 38591349 Free PMC article.
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer.
Perera M, Roberts MJ, Klotz L, Higano CS, Papa N, Sengupta S, Bolton D, Lawrentschuk N. Perera M, et al. Nat Rev Urol. 2020 Aug;17(8):469-481. doi: 10.1038/s41585-020-0335-7. Epub 2020 Jun 30. Nat Rev Urol. 2020. PMID: 32606361 Review.
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
Siewe N, Friedman A. Siewe N, et al. PLoS One. 2022 Jan 11;17(1):e0262453. doi: 10.1371/journal.pone.0262453. eCollection 2022. PLoS One. 2022. PMID: 35015785 Free PMC article.
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.
Tonry C, Finn S, Armstrong J, Pennington SR. Tonry C, et al. Clin Proteomics. 2020 Nov 20;17(1):41. doi: 10.1186/s12014-020-09305-7. Clin Proteomics. 2020. PMID: 33292167 Free PMC article. Review.

See all "Cited by" articles

References

1. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90. - PMC - PubMed
1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12. - PubMed
1. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51. - PubMed
1. Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211-28. - PubMed
1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90. - PMC - PubMed

[2] Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90. - PMC - PubMed

[3] Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12. - PubMed

[4] Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9-12. - PubMed

[5] Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51. - PubMed

[6] Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51. - PubMed

[7] Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211-28. - PubMed

[8] Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008;9:211-28. - PubMed

[9] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. - PubMed

[10] Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

Affiliation

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources